A startup company developing treatments for inflammatory diseases based on a research partnership between The University of Queensland and Trinity College Dublin (TCD) has been acquired in a landmark deal – one of the largest in Australian and Irish biotech history.
Inflazome has been acquired by Roche for an upfront cash payment of €380 million (about $A617 million), plus additional payments based on the achievement of certain milestones.
The company was founded in 2016 following a research collaboration between UQ and TCD, with UQ’s technology transfer company UniQuest leading the commercialisation of the resulting intellectual property (IP).
